NASDAQ$RIGL
Rigel Pharmaceuticals Inc · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
Reported financial results for the second quarter ended June 30, 2021, including sales of TAVALISSE.
Rigel Pharmaceuticals reported a net loss of $13.8 million for the second quarter of 2021, with total revenues of $26.3 million, including TAVALISSE net product sales of $17.1 million.
- TAVALISSE sales are growing as Rigel accesses more clinicians in-person.
- Rigel is expanding its commercial team to increase impact as physicians and patients return to the clinic.
- Phase 3 clinical trial of fostamatinib in hospitalized COVID-19 patients is rapidly enrolling.
- Phase 3 clinical trial of fostamatinib in wAIHA is nearing its enrollment goal.
Headline financials
Revenue & EPS history
Rigel · Revenue · Quarterly
$26.3M
Revenue by segment
Rigel · $3.7M total across 1 segment · Q2 2021
- Collaboration Revenue$3.7M—100.0%
Forward guidance
Rigel is well-positioned to execute on several key milestones that have the potential to be important inflection points for the company.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2021
+0.2%
Avg return
Earnings day
+2.5%
Avg return
5 days after
+2.8%
Avg return
30 days after
38%
25 / 65 earnings
Positive
+46.4%
Q3 2024
Best reaction
-18.7%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -4.8% | -11.8% | +2.3% | |
| Q4 2025 | -10.2% | -15.0% | -16.6% | |
| Q3 2025 | -2.6% | +10.6% | +35.4% | |
| Q1 2025 | +0.9% | +1.9% | +17.7% | |
| Q4 2024 | -8.1% | -11.5% | -21.9% | |
| Q3 2024 | +46.4% | +80.5% | +68.8% | |
| Q2 2024 | +12.2% | +16.0% | +52.4% | |
| Q1 2024 | -18.7% | -19.7% | -21.3% | |
| Q4 2023 | +6.1% | +6.8% | -12.2% | |
| Q3 2023 | +5.8% | -2.4% | +35.7% | |
| Q2 2023 | -6.5% | -11.6% | -17.4% | |
| Q1 2023 | -3.4% | -0.8% | +17.6% | |
| Q4 2022 | +17.8% | +4.6% | -17.8% | |
| Q3 2022 | +5.3% | +4.3% | +18.6% | |
| Q2 2022 | +16.5% | +25.6% | +27.3% | |
| Q1 2022 | +7.3% | -9.8% | -32.5% | |
| Q4 2021 | +21.1% | +21.1% | +19.1% | |
| Q3 2021 | -1.7% | -8.8% | -26.3% | |
| Q2 2021 | -7.2% | -5.2% | +3.2% | |
| Q1 2021 | -5.2% | -7.8% | +15.7% | |
| Q4 2020 | -14.3% | -14.1% | -23.3% | |
| Q3 2020 | -3.0% | +1.5% | +14.1% | |
| Q2 2020 | +3.7% | +6.2% | -4.5% | |
| Q1 2020 | -2.2% | -2.7% | +2.2% | |
| Q4 2019 | -2.3% | +0.5% | -27.6% | |
| Q3 2019 | -1.9% | +4.7% | -5.1% | |
| Q2 2019 | +8.1% | +1.9% | -15.7% | |
| Q1 2019 | -5.5% | -6.7% | -14.7% | |
| Q4 2018 | -0.9% | -1.8% | +13.7% | |
| Q3 2018 | +7.2% | -2.7% | -3.8% | |
| Q2 2018 | +10.2% | +1.1% | +16.8% | |
| Q1 2018 | +5.3% | +7.2% | -10.0% | |
| Q4 2017 | +13.5% | +14.5% | -18.1% | |
| Q3 2017 | +1.1% | +1.6% | +2.4% | |
| Q2 2017 | -1.3% | +1.7% | +7.6% | |
| Q1 2017 | -9.9% | -9.2% | -19.1% | |
| Q4 2016 | +2.6% | +0.8% | +14.3% | |
| Q3 2016 | -3.1% | +1.5% | -3.5% | |
| Q2 2016 | +14.3% | +22.7% | +37.5% | |
| Q1 2016 | -10.9% | — | — | |
| Q4 2015 | -6.3% | — | — | |
| Q3 2015 | +8.9% | — | — | |
| Q2 2015 | +4.6% | — | — | |
| Q1 2015 | -10.5% | — | — | |
| Q4 2014 | -1.0% | — | — | |
| Q3 2014 | -1.5% | — | — | |
| Q2 2014 | -6.2% | — | — | |
| Q1 2014 | -10.6% | — | — | |
| Q4 2013 | +17.5% | — | — | |
| Q3 2013 | -9.3% | — | — | |
| Q2 2013 | +2.8% | — | — | |
| Q1 2013 | -0.6% | — | — | |
| Q4 2012 | +5.5% | — | — | |
| Q3 2012 | +2.7% | — | — | |
| Q2 2012 | -7.1% | — | — | |
| Q1 2012 | -2.1% | — | — | |
| Q4 2009 | -9.0% | — | — | |
| Q4 2011 | -9.0% | — | — | |
| Q3 2010 | -5.9% | — | — | |
| Q3 2011 | -5.9% | — | — | |
| Q2 2010 | -3.3% | — | — | |
| Q4 2010 | -3.3% | — | — | |
| Q2 2011 | -3.3% | — | — | |
| Q1 2011 | -11.5% | — | — | |
| Q1 2010 | -5.3% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro